Previous 10 | Next 10 |
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed noted expert in internal medicine, Dr. Jeff Toll , to its medical advisory board . As an industry thought-lead...
NEW YORK, June 09, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported record net revenues of $3.2 million for the month of May, up 274% versus May 2019. Combined net revenues for April and May totaled $6.3 mi...
Conversion Labs ( OTCQB:CVLB ): Q1 GAAP EPS of -$0.05. More news on: Conversion Labs, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported results for the first quarter ended March 31, 2020. Q1 2020 Financial Highlights Revenue was a record $4.3 million, up 59% ve...
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has begun the roll out of a new cloud-based, end-to-end telemedicine platform, Veritas MD . The platform builds upon Conversion Labs’ exis...
Conversion Labs ( OTCQB:CVLB +5.3% ) reported preliminary unaudited revenue of ~$4.3M, up 60% Y/Y for Q1. More news on: Conversion Labs, Inc., Consumer stocks news, , Read more ...
NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported preliminary unaudited revenue of approximately $4.3 million for the first quarter ended March 31, 2020, up 60% compared to the same year-ago p...
NEW YORK, April 14, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed Dr. Jeremy Fine , a noted expert in internal medicine, to its medical advisory board . Dr. Fine will be involved in guidi...
Conversion Labs ( OTCQB:CVLB ): Q4 GAAP EPS of -$0.01. Revenue of $3.94M (+80.7% Y/Y) Press Release More news on: Conversion Labs, Inc., Earnings news and commentary, Consumer stocks news, ,
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported results for the fourth quarter and full year ended December 31, 2019. Quarterly comparisons are to the same year-ago quarter. Fin...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, has been invited to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held on February 17...
NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge ser...
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc . (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continu...